MANUFACTURING
NOVEL DRUG DELIVERY SYSTEMS
Industrial advancements Development of an existing API molecule from an immediate release form to a novel delivery system can improve its performance in terms of Efficacy, Specificity, Safety and patient compliance. Its Importance is evident from the fact that Global ‘Novel Drug Delivery Systems Market’ 2020 is expected to grow at a CAGR of roughly 2.2 per cent over the next five years and will reach 30300 million USD in 2024, from 26500 million USD in 2019. Farhan Jalees Ahmad, Professor, School of Pharmaceutical Education & Research, Jamia Hamdard
60
P H A RM A F O C U S A S I A
ISSUE 41 - 2020
C
onventional dosage forms and delivery systems present several challenges in treatment of diseases like poor bioavailability, high dose, frequent administration, systemic adverse effects, etc. Also, increasing prevalence of chronic diseases, high demand for non-invasive administration of drugs, need for high bioavailability and targeted delivery of drugs for lesser side effects have paved the way for innovation in drug delivery systems. Therefore, pharmaceutical companies are focused on designing novel drug delivery systems to overcome the limitations of using conventional dosage forms. For this reason, novel drug delivery systems might be among the fastest expanding segments in the drug industry.
